A comparative study of inhaled ciclesonide 160 µg/day and fluticasone propionate 176 µg/day in children with asthma

摘要: Ciclesonide (CIC) is an inhaled corticosteroid (ICS) with high anti-inflammatory activity and low incidence of local systemic adverse effects. The objective this study was to compare the efficacy safety CIC fluticasone propionate (FP) in children adolescents persistent asthma. This a 12-week, randomized, double blind, parallel-group study. After 2-to 4-week baseline period, total 556 (ages 6–15 years) asthma (forced expiratory volume 1 sec [FEV1], 50% 90% predicted) were treated twice daily 80 µg (ex-actuator, equivalent 100 ex-valve) or FP 88 administered via hydrofluoroalkane-propelled metered-dose inhaler. A statistically significant increase from observed FEV1 for both (285 ± 16 ml) (285 ± 15 (P < 0.0001 both) morning evening peak flow both). Significant improvements seen symptoms, use rescue medication, symptom-free days treatment groups, without any differences between groups changes baseline. Two FP-treated patients experienced oral candidiasis one patient voice alteration. Creatinine-adjusted 24-hr urine cortisol levels increased by 10% group (P < 0.05) 6% (not significant). 160 µg/day comparable those 176 Pediatr Pulmonol. 2006, 41:954–961. © 2006 Wiley-Liss, Inc.